Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Eurofins Ntd Llc |
RCV000370731 | SCV000343518 | uncertain significance | not provided | 2016-07-14 | criteria provided, single submitter | clinical testing | |
Invitae | RCV001057302 | SCV001221787 | uncertain significance | Isovaleryl-CoA dehydrogenase deficiency | 2024-01-29 | criteria provided, single submitter | clinical testing | This sequence change affects codon 155 of the IVD mRNA. It is a 'silent' change, meaning that it does not change the encoded amino acid sequence of the IVD protein. This variant also falls at the last nucleotide of exon 4, which is part of the consensus splice site for this exon. This variant is present in population databases (no rsID available, gnomAD 0.008%). This variant has not been reported in the literature in individuals affected with IVD-related conditions. ClinVar contains an entry for this variant (Variation ID: 289203). Variants that disrupt the consensus splice site are a relatively common cause of aberrant splicing (PMID: 17576681, 9536098). Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may disrupt the consensus splice site. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Natera, |
RCV001057302 | SCV001461292 | uncertain significance | Isovaleryl-CoA dehydrogenase deficiency | 2020-09-16 | no assertion criteria provided | clinical testing |